Amwill Health Care Limited

BSE: AMWILL · Pharmaceuticals · sector

₹41.61BSE close 2026-10-26

Key numbers

Market cap₹83 cr

Price₹41.61

52w high / low₹57 / ₹29

P/E7.3xSector median 27.9x

P/B1.3xSector median 2.9x

Book value₹31.6

Dividend yield–Sector median 0.48%

ROE19.6%Sector median 11.7%

ROCE24.3%Sector median 12.3%

OPM28.6%Sector median 14.0%

Debt / equity–Sector median 0.16x

EV/EBITDA4.5xSector median 18.6x

Interest cover–

Current ratio10.69x

Sales growth 3y–Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Sep 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Other income was 26% of net profit in the last 12 months.
No dividend in the last 2 financial years.
Price ₹41.61 on 2026-10-26: -27.0% from the 52-week high, +43.9% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹98.40 · low ₹30.39

Quarterly results

₹ cr	Mar 2025	Sep 2025	Mar 2026	Sep 2026
Revenue	17	21	24	23
EBITDA	3	4	9	3
OPM %	16.1%	19.4%	36.6%	15.2%
Other income	1	1	2	2
Net profit	4	4	8	4
EPS (₹)	0.00	1.94	3.77	1.84

Standalone figures where filed. Latest quarter Sep 2026.

Profit & loss (yearly)

₹ cr	FY25	FY26	TTM
Revenue	41	45	45
EBITDA	12	13	13
Net profit	11	11	11
EPS (₹)	0.00	5.71	5.71
Revenue growth		+12.1%	–
Profit growth		+6.4%	–
Dividend / share (₹)	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	–	–	–
Net profit	–	–	–
EPS	–	–	–
Share price	–	– (2y)	-14.4%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	49	61
Cash & equivalents	3	47
Total assets	71	87
Fixed assets	1	1
Investments	0	0
Inventory	1	1

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	6	8
Cash from investing	-46	6
Cash from financing	41	-0
Capex	1	1
Free cash flow	5	7

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	21.8%	18.9%
ROCE %	24.2%	25.4%
Inventory days	18	22
Working capital days	181	530

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
AMWILL	₹83 cr	7.3x	1.3x	19.6%	24.3%	28.6%	–	–

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-10-30	Dividend	Interim Dividend Rs 0.5
2026-08-07	Dividend	Final Dividend Rs 0.5

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	AMWILL
BSE code	544353
ISIN	INE0U2L01017
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.